Dr. Douglas Loe

Leede Financial Inc.

Douglas Loe, managing director and analyst at Leede Jones Gable, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors. Loe has been recognized as one of Canada's top healthcare analysts by the StarMine Analysts Awards, based on the quality of his recommendations to institutional investors. He holds a Ph.D. in biochemistry.

Recent Articles about Rakovina Therapeutics Inc.

Seeking Formulation of New Drug, Biopharma Co. Signs LOI 09/05/2025

Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report.

Q1/25 Financials of Cancer Drug Developer Released 06/12/2025

Rakovina Therapeutics Inc.'s (RKV:TSX.V) CA$4 million equity offering is nearing completion, noted a Leede Financial Inc. report.